Old Web
English
Sign In
Acemap
>
authorDetail
>
Mª. T. Cano
Mª. T. Cano
University of Córdoba (Spain)
Capecitabine
Clinical trial
Population
Oxaliplatin
Oncology
2
Papers
7
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02
2015
Cancer Chemotherapy and Pharmacology
Fernando Rivera
B. Massuti
Matilde Salcedo
J. Sastre
J. Martínez Galán
Manuel Valladares-Ayerbes
R. Serrano
Mª. L. García de Paredes
Jose Luis Manzano
Maica Galán
Maria Alsina
A L Yuste Izquierdo
Carlos J.Lopez
E. Díaz Rubio
Veronica Conde
Margarita Reboredo
Mª. T. Cano
V. Pachón
E. Aranda
Show All
Source
Cite
Save
Citations (7)
Phase II trial of miniDOX (reduced-dose docetaxel/oxaliplatin/capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC): TTD 08-02.
2013
Journal of Clinical Oncology
Fernando Rivera
Bartomeu Massuti
Matilde Salcedo
Javier Sastre
J. Martínez Galán
Manuel Valladares-Ayerbes
R. Serrano
Mª. L. García de Paredes
Jose Luis Manzano
Maica Galán
Maria Alsina
A L Yuste Izquierdo
Carlos J. López
Eduardo Diaz Rubio
V. Conde
Margarita Reboredo
Mª. T. Cano
V. Pachón
Enrique Aranda
Show All
Source
Cite
Save
Citations (0)
1